UA40663C2 - Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання - Google Patents

Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання

Info

Publication number
UA40663C2
UA40663C2 UA97073814A UA97073814A UA40663C2 UA 40663 C2 UA40663 C2 UA 40663C2 UA 97073814 A UA97073814 A UA 97073814A UA 97073814 A UA97073814 A UA 97073814A UA 40663 C2 UA40663 C2 UA 40663C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
oral administration
solid pharmaceutical
controlled release
composition adapted
Prior art date
Application number
UA97073814A
Other languages
English (en)
Russian (ru)
Inventor
Невілл У. Борд
Невилл У. Борд
Елан Ф. Кармоуді
Элан Ф. Кармоуди
Лайєм К. Філі
Лайем К. Фили
Брайєн К. Уізерс
Брайен К. Уизерс
Original Assignee
Ебботт Лабораторіз
Ебботт Лабораториз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24298013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA40663(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ебботт Лабораторіз, Ебботт Лабораториз filed Critical Ебботт Лабораторіз
Publication of UA40663C2 publication Critical patent/UA40663C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується форми перорального дозування контрольованого поступового вивільнення для щонайменш одного малорозчинного основного лікарського засобу, що дозволить змінити режим щоденного дозування. Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для перорального вживання, що включає водорозчинну сіль альгінової кислоти, причому вона додатково містить терапевтично ефективну кількість, принаймні, одного лікарського засобу, що має розчинність у воді менше, ніж 1 частина на ЗО частин води, і ефективну кількість органічної карбонової кислоти для полегшення розчинення лікарського засобу.
UA97073814A 1995-12-19 1996-11-25 Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання UA40663C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/574,877 US5705190A (en) 1995-12-19 1995-12-19 Controlled release formulation for poorly soluble basic drugs
PCT/US1996/018960 WO1997022335A1 (en) 1995-12-19 1996-11-25 A controlled release formulation for poorly soluble basic drugs

Publications (1)

Publication Number Publication Date
UA40663C2 true UA40663C2 (uk) 2001-08-15

Family

ID=24298013

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97073814A UA40663C2 (uk) 1995-12-19 1996-11-25 Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання

Country Status (26)

Country Link
US (1) US5705190A (uk)
EP (1) EP0799028B1 (uk)
JP (1) JP3292732B2 (uk)
KR (1) KR100632187B1 (uk)
CN (1) CN1131027C (uk)
AR (1) AR004391A1 (uk)
AT (2) ATE170744T1 (uk)
AU (1) AU701268B2 (uk)
CA (1) CA2209714C (uk)
CZ (1) CZ289158B6 (uk)
DE (2) DE29624506U1 (uk)
DK (1) DK0799028T3 (uk)
ES (1) ES2122810T3 (uk)
HU (1) HUP9800516A3 (uk)
IL (1) IL121275A (uk)
IT (1) ITMI20050383U1 (uk)
NZ (1) NZ323332A (uk)
PL (1) PL186696B1 (uk)
PT (1) PT103379B (uk)
RO (1) RO117501B1 (uk)
RU (1) RU2142793C1 (uk)
TR (1) TR199800777T2 (uk)
TW (1) TW429154B (uk)
UA (1) UA40663C2 (uk)
WO (1) WO1997022335A1 (uk)
ZA (1) ZA9610110B (uk)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758244B2 (en) 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SK282427B6 (sk) * 1997-06-11 2002-01-07 Abbott Laboratories Pevná farmaceutická kompozícia s riadeným uvoľňovaním
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
IN186245B (uk) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
DK1064942T3 (da) * 1998-03-26 2004-11-01 Fujisawa Pharmaceutical Co Sustained release-fremstilling af et makrolid
IT1314185B1 (it) * 1998-08-21 2002-12-06 Novartis Ag Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
IN192748B (uk) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
RU2200002C1 (ru) * 2001-07-30 2003-03-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Твердая фармацевтическая композиция и способ ее получения
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
CN1575164A (zh) * 2001-08-29 2005-02-02 兰贝克赛实验室有限公司 克拉霉素或替硝唑的控释制剂
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
US20030091627A1 (en) * 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
CA2465405A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
RU2207120C1 (ru) * 2001-12-29 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Лекарственное средство брилид антибиотического действия
RU2201751C1 (ru) * 2002-01-23 2003-04-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая антигипертензивным и диуретическим действием, и способ её получения
GB2384986B (en) * 2002-02-12 2004-01-07 Reckitt Benckiser Healthcare Compositions for the treatment of disorders of the upper gastrointestinal tract
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
SI21300A (sl) * 2002-10-08 2004-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtske formulacije z alginati
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
RU2214234C1 (ru) * 2002-11-25 2003-10-20 Нестерук Владимир Викторович ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ СВОЙСТВАМИ КАРДИОСЕЛЕКТИВНОГО β1-АДРЕНОБЛОКАТОРА
GB0230034D0 (en) * 2002-12-23 2003-01-29 Biochemie Gmbh Organic compounds
EP1592453A1 (en) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
RU2222333C1 (ru) * 2003-03-06 2004-01-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция с антибактериальной активностью и способ ее получения
US8507000B2 (en) * 2003-05-06 2013-08-13 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
RU2240112C1 (ru) * 2003-06-09 2004-11-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая бактериостатическим действием, и способ ее изготовления
US7476403B2 (en) * 2003-06-16 2009-01-13 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8758820B2 (en) * 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
JP2007502294A (ja) * 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004275594A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
CN100435847C (zh) * 2004-05-13 2008-11-26 宝龄富锦生技股份有限公司 含有难溶解性主药之持续释放配方
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
RU2272626C1 (ru) * 2004-09-06 2006-03-27 Открытое акционерное общество "Щелковский витаминный завод" Антипротозойное средство на основе метронидазола
CN1322866C (zh) * 2004-10-12 2007-06-27 广州贝氏药业有限公司 一种多单元缓释制剂
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US20070128272A1 (en) * 2005-12-07 2007-06-07 Zerbe Horst G Multi-vitamin and mineral supplement
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
RU2428176C2 (ru) * 2006-01-27 2011-09-10 Юранд, Инк. Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (en) * 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
KR101561571B1 (ko) * 2007-12-28 2015-10-19 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 글리코겐과 알긴산염의 회합을 기초로 한 서방형 제제
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
JP5960594B2 (ja) * 2009-05-29 2016-08-02 テトラ ラバル ホールデイングス エ フイナンス ソシエテ アノニム 磁化可能な部分を備えたパッケージ材
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102470108A (zh) * 2009-07-07 2012-05-23 桑诺维恩药品公司 非pH依赖型制剂(6-(5-氯-2-吡啶基)-5-[(4-甲基-1-哌嗪基)羰氧基]-7-氧代-6，7-二氢-5H-吡咯并[3，4-b]吡嗪)
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
US20120219625A1 (en) * 2009-09-02 2012-08-30 Bernard Charles Sherman Clarithromycin extended-release tablet
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012083017A2 (en) 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
DE102013202703B4 (de) 2013-02-20 2020-03-12 Siemens Healthcare Gmbh Vorrichtung und Verfahren zur Kollisionserkennung bei einem medizintechnischen Gerät
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
WO2017027778A1 (en) 2015-08-13 2017-02-16 Temple University-Of The Commonwealth System Of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110869000A (zh) * 2017-05-11 2020-03-06 斯泰迪麦德有限公司 增强溶解度的含药制剂
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CN111184699A (zh) * 2020-04-09 2020-05-22 河北大学 一种硝苯地平控释胶囊及其制备方法
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296140A (en) * 1977-03-08 1981-10-20 Tri/Valley Growers Molded gelled pimiento body
GB1566609A (en) * 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
TR199800777T2 (xx) 1998-07-21
EP0799028A1 (en) 1997-10-08
HUP9800516A3 (en) 2000-07-28
CN1131027C (zh) 2003-12-17
CZ221297A3 (en) 1997-12-17
WO1997022335A1 (en) 1997-06-26
JPH11513406A (ja) 1999-11-16
CN1205629A (zh) 1999-01-20
DE69600620D1 (de) 1998-10-15
JP3292732B2 (ja) 2002-06-17
CA2209714A1 (en) 1997-06-26
US5705190A (en) 1998-01-06
KR19980701832A (ko) 1998-06-25
HUP9800516A2 (hu) 1998-08-28
AR004391A1 (es) 1998-11-04
ATE170744T1 (de) 1998-09-15
ES2122810T3 (es) 1998-12-16
NZ323332A (en) 1998-04-27
TW429154B (en) 2001-04-11
PT103379B (pt) 2007-02-28
IL121275A0 (en) 1998-01-04
CZ289158B6 (cs) 2001-11-14
MX9706031A (es) 1997-11-29
DK0799028T3 (da) 1999-06-07
PL321363A1 (en) 1997-12-08
AT7918U1 (de) 2005-11-15
HK1016873A1 (en) 1999-11-12
DE29624506U1 (de) 2004-12-09
RO117501B1 (ro) 2002-04-30
DE69600620T2 (de) 1999-05-06
ITMI20050383U1 (it) 2006-06-20
PL186696B1 (pl) 2004-02-27
KR100632187B1 (ko) 2008-09-24
CA2209714C (en) 2002-07-30
IL121275A (en) 2003-10-31
AU701268B2 (en) 1999-01-21
RU2142793C1 (ru) 1999-12-20
EP0799028B1 (en) 1998-09-09
ZA9610110B (en) 1997-06-18
AU1025297A (en) 1997-07-14

Similar Documents

Publication Publication Date Title
UA40663C2 (uk) Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання
MY125662A (en) Pharmaceutical formulations containing darifenacin
BG104727A (en) Pharmaceutical composition of topiramate
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
NZ514574A (en) Novel method of treatment
BG104476A (en) Therapeutical form for tolterodin with controlled release
MX9709094A (es) Formulaciones farmaceuticas de derivados muy lipofilos de la comptotecina.
IS8807A (is) Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
FI973518A7 (fi) Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
PL356166A1 (en) Pharmaceutical formulation containing tolterodine and its use
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
AU678344B2 (en) Lipophilic oligosaccharide antibiotic salt compositions
BG105173A (en) Novel salt form of pantoprazole
MXPA04001933A (es) Composicion farmaceutica que comprende lumiracoxib.
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
ZA963584B (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
EP0271151A3 (en) Azumolene dosage form